Akebia's Vadadustat Misses In Non-Dialysis CKD, But Filings Still Planned For 2021
Executive Summary
HIF-PHI inhibitor failed to show non-inferiority to ESAs in the primary cardiovascular safety endpoint of a Phase III program for the treatment of anemia due to chronic kidney disease.
You may also be interested in...
Restructuring On The Table For FibroGen After Roxadustat Rejection
As anticipated, the FDA issued a complete response letter for roxadustat. While the drug is expected to win EU approval, it is unclear if FibroGen and AstraZeneca will be willing to fund another trial.
Roxadustat CKD Doubts Fanned By FibroGen Data Blunder
AstraZeneca's partner FibroGen stunned investors and regulators by announcing that previously disclosed cardiovascular safety data for CKD candidate roxadustat included changes made post hoc, rather than as pre-specified with the US FDA.
One To Watch: Ruling On AZ’s First-In-Class Anemia Drug Roxadustat Expected Shortly
AstraZeneca is in pole position to open up the HIF-PH inhibitor market – but GSK has a rival in the wings.